Combination Anti-Integrin and VEGF Therapy for Tumor Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic therapies, such as those targeting VEGF, have shown limited clinical success in inhibiting tumor vascularization, as tumor cells often develop resistance by utilizing alternative vascularization methods, such as co-option of existing vessels, which are not adequately addressed by singular therapeutic strategies.
Innovation Solution
A combination therapy using a VEGF inhibitor and a beta-1 integrin blocker, which targets both angiogenic and adhesive signaling pathways, to inhibit tumor cell growth by depriving tumors of an adequate blood supply and preventing vessel co-option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-angiogenic therapy targets only VEGF pathways, then specific anti-cancer effect is achieved, but tumor cells develop resistance through alternative vascularization methods
Solution Approach 1:
The patent combines two distinct therapeutic agents: a VEGF inhibitor (bevacizumab) and a beta-1 integrin blocking agent (AIIB2 antibody). This combination targets both angiogenic pathways (VEGF-mediated new vessel formation) and adhesive pathways (integrin-mediated vessel co-option), preventing tumor cells from developing resistance through alternative vascularization methods
Solution Approach 2:
The therapy uses a composite approach by administering two different types of antibodies with distinct mechanisms of action. The VEGF inhibitor blocks angiogenic signaling while the beta-1 integrin blocker prevents adhesive interactions, creating a multi-targeted therapeutic strategy that addresses both angiogenesis and vessel co-option
2Ease of operation
If single-agent anti-angiogenic therapy is used, then treatment simplicity is maintained, but clinical success is limited due to tumor vascularization alternatives
Solution Approach 1:
The patent merges two antibody therapies into a combination regimen that can be administered together or in alternating cycles. This maintains relative treatment simplicity while significantly improving clinical success by blocking both angiogenic and adhesive vascularization pathways simultaneously
3Reliability
If beta-1 integrin blocking is added to VEGF inhibition, then both angiogenic and adhesive signaling are targeted, but treatment complexity increases
Solution Approach 1:
The patent describes alternating cycle therapy where patients receive VEGF inhibitor treatment in one cycle followed by beta-1 integrin blocker treatment in the next cycle. This periodic administration strategy maintains high therapeutic efficacy by sequentially targeting both pathways while reducing the complexity of simultaneous combination therapy
Data Source
AI summary
Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.